What's Happening?
Bayer has announced the final results of the Phase III PEACE-3 trial, which demonstrated that the combination of XOFIGO (radium-223 dichloride) and enzalutamide significantly improved overall survival in men with metastatic castration-resistant prostate
cancer (mCRPC) and bone metastases. The trial showed a 24% reduction in the risk of death compared to enzalutamide alone. The median overall survival for patients receiving the combination was 38.2 months, compared to 32.6 months for those on enzalutamide alone. These findings will be presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in 2026. The trial was conducted by the European Organization for Research and Treatment of Cancer and involved multiple international cancer research groups.
Why It's Important?
The results of the PEACE-3 trial are significant as they offer a new potential treatment strategy for patients with mCRPC, a group that typically faces a poor prognosis. The combination therapy could become a new standard of care, improving survival rates and quality of life for these patients. This development underscores Bayer's commitment to advancing cancer treatment and highlights the importance of international collaboration in clinical research. The findings may influence clinical decision-making and encourage further research into combination therapies for prostate cancer.
What's Next?
Following the presentation of the trial results, the medical community will likely evaluate the potential integration of this combination therapy into standard treatment protocols for mCRPC. Regulatory bodies may also consider these findings for approval processes. Bayer and its partners may continue to explore additional combination therapies and further research to enhance treatment options for prostate cancer patients.
